Nadim Ahmed
Net worth: 2 M $ as of 30/06/2026
Net worth: 2 M $ as of 30/06/2026
Mr. Nadim Ahmed is a President, Chief Executive Officer & Director at Cullinan Therapeutics, Inc., a President, Chief Executive Officer & Director at Cullinan Mica Corp.
and a President, Chief Executive Officer & Director at Cullinan Pearl Corp.
He is on the Board of Directors at Disc Medicine, Inc., Cullinan Therapeutics, Inc., Family Promise, Cullinan Mica Corp.
and Cullinan Pearl Corp.
Mr. Ahmed was previously employed as a President, Chief Executive Officer & Director by Cullinan Oncology LLC, a President-Hematology by Bristol Myers Squibb Co., a President-Global Hematology & Oncology by Celgene Corp., and a Senior Marketing Director-Hematologic Oncology by GlaxoSmithKline LLC.
He received his undergraduate degree from the University College London and a graduate degree from Loughborough University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/04/2026 | 1,35,921 ( 0.23% ) | 2 M $ | 30/06/2026 |
| Companies | Position | Start |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Chief Executive Officer | 18/10/2021 |
| DISC MEDICINE, INC. | Director/Board Member | 14/07/2025 |
Family Promise
Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Director/Board Member | - |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Chief Executive Officer | - |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Chief Executive Officer | - |
| Companies | Position | End |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2021 |
| CELGENE | Corporate Officer/Principal | 01/11/2019 |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Corporate Officer/Principal | 01/03/2010 |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 11 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Loughborough University
Loughborough University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Family Promise
Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Commercial Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Finance |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Health Technology |
Cullinan Oncology, Inc.
Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Disc Medicine, Inc.
Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions